220 related articles for article (PubMed ID: 21410054)
21. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients.
Stärkel P; Stoffel M; Lerut J; Horsmans Y
Liver Transpl; 2005 Oct; 11(10):1228-34. PubMed ID: 16184571
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation.
Yuefeng M; Weili F; Wenxiang T; Ligang X; Guiling L; Hongwei G; Wencai L; Xiaoguang W; Wei M; Zhongyi F
Clin Transplant; 2011; 25(4):517-22. PubMed ID: 20560989
[TBL] [Abstract][Full Text] [Related]
23. Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens.
Anderson RD; Chinnakotla S; Guo L; Perrillo RP; Klintmalm GB; Davis GL
Clin Transplant; 2007; 21(4):510-7. PubMed ID: 17645711
[TBL] [Abstract][Full Text] [Related]
24. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant.
Tchervenkov JI; Tector AJ; Barkun JS; Sherker A; Forbes CD; Elias N; Cantarovich M; Cleland P; Metrakos P; Meakins JL
Ann Surg; 1997 Sep; 226(3):356-65; discussion 365-8. PubMed ID: 9339942
[TBL] [Abstract][Full Text] [Related]
25. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation.
Yao FY; Osorio RW; Roberts JP; Poordad FF; Briceno MN; Garcia-Kennedy R; Gish RR
Liver Transpl Surg; 1999 Nov; 5(6):491-6. PubMed ID: 10545536
[TBL] [Abstract][Full Text] [Related]
26. Subcutaneous administration of hepatitis B immune globulin in combination with lamivudine following orthotopic liver transplantation: effective prophylaxis against recurrence.
Powell JJ; Apiratpracha W; Partovi N; Erb SR; Scudamore CH; Steinbrecher UP; Buczkowski AK; Chung SW; Yoshida EM
Clin Transplant; 2006; 20(4):524-5. PubMed ID: 16842532
[TBL] [Abstract][Full Text] [Related]
27. Prevention of hepatitis B recurrence after liver transplantation using lamivudine and hepatitis B immune globulin.
Ołdakowska-Jedynak U; Paczek L; Foroncewicz B; Mucha K; Nyckowski P; Zieniewicz K; Ziarkiewicz-Wróblewska B; Ziółkowski J; Pilecki T; Patkowski W; Górnicka B; Paczkowska A; Krawczyk M
Ann Transplant; 2007; 12(3):28-32. PubMed ID: 18290567
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B prophylaxis using lamivudine and individualized low-dose hepatitis B immunoglobulin in living donor liver transplantation.
Jiang L; Yan L; Wen T; Li B; Zhao J; Yang J; Xu M; Wang W
Transplant Proc; 2013; 45(6):2326-30. PubMed ID: 23953544
[TBL] [Abstract][Full Text] [Related]
29. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
[TBL] [Abstract][Full Text] [Related]
30. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin.
Terrault NA; Zhou S; Combs C; Hahn JA; Lake JR; Roberts JP; Ascher NL; Wright TL
Hepatology; 1996 Dec; 24(6):1327-33. PubMed ID: 8938155
[TBL] [Abstract][Full Text] [Related]
31. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors.
Dodson SF; Bonham CA; Geller DA; Cacciarelli TV; Rakela J; Fung JJ
Transplantation; 1999 Oct; 68(7):1058-61. PubMed ID: 10532552
[TBL] [Abstract][Full Text] [Related]
32. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.
Naoumov NV; Lopes AR; Burra P; Caccamo L; Iemmolo RM; de Man RA; Bassendine M; O'Grady JG; Portmann BC; Anschuetz G; Barrett CA; Williams R; Atkins M
J Hepatol; 2001 Jun; 34(6):888-94. PubMed ID: 11451173
[TBL] [Abstract][Full Text] [Related]
33. Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation.
Lu AW; Zheng SS; Wu MP; Shen Y; Yang RW
Hepatobiliary Pancreat Dis Int; 2008 Aug; 7(4):357-61. PubMed ID: 18693169
[TBL] [Abstract][Full Text] [Related]
34. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors?
Loss GE; Mason AL; Nair S; Blazek J; Farr G; Guo L; Cohen AJ; Eason JD
Liver Transpl; 2003 Dec; 9(12):1258-64. PubMed ID: 14625825
[TBL] [Abstract][Full Text] [Related]
35. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.
Markowitz JS; Martin P; Conrad AJ; Markmann JF; Seu P; Yersiz H; Goss JA; Schmidt P; Pakrasi A; Artinian L; Murray NG; Imagawa DK; Holt C; Goldstein LI; Stribling R; Busuttil RW
Hepatology; 1998 Aug; 28(2):585-9. PubMed ID: 9696028
[TBL] [Abstract][Full Text] [Related]
36. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation.
Di Paolo D; Tisone G; Piccolo P; Lenci I; Zazza S; Angelico M
Transplantation; 2004 Apr; 77(8):1203-8. PubMed ID: 15114086
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.
Sánchez-Fueyo A; Rimola A; Grande L; Costa J; Mas A; Navasa M; Cirera I; Sánchez-Tapias JM; Rodés J
Hepatology; 2000 Feb; 31(2):496-501. PubMed ID: 10655276
[TBL] [Abstract][Full Text] [Related]
38. Evolving experience of hepatitis B virus prophylaxis in liver transplantation.
Honaker MR; Shokouh-Amiri MH; Vera SR; Alloway RR; Grewal HP; Hardinger KL; Kizilisik AT; Bagous T; Trofe J; Stratta RJ; Egidi MF; Gaber AO
Transpl Infect Dis; 2002 Sep; 4(3):137-43. PubMed ID: 12421458
[TBL] [Abstract][Full Text] [Related]
39. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.
Fernández I; Loinaz C; Hernández O; Abradelo M; Manrique A; Calvo J; Manzano M; García A; Cambra F; Castellano G; Jiménez C
Transpl Infect Dis; 2015 Oct; 17(5):695-701. PubMed ID: 26257166
[TBL] [Abstract][Full Text] [Related]
40. De novo hepatitis b prophylaxis with hepatitis B virus vaccine and hepatitis B immunoglobulin in pediatric recipients of core antibody-positive livers.
Lee S; Kim JM; Choi GS; Park JB; Kwon CH; Choe YH; Joh JW; Lee SK
Liver Transpl; 2016 Feb; 22(2):247-51. PubMed ID: 26600319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
